This questionnaire is to be filled in by the project **only** if your Project Officer has asked you to do so. The European Commission will not make public any data entered in this form.

**DG CONNECT Innovation Questionnaire**

**Note:** the first 16 questions below are to be answered for **each** innovation the project develops (up to a maximum of 3 innovations).

**1) Describe the innovation (in less than 300 characters, spaces included):**

Alternative method for the fabrication of metal micro/nanostructures from metal-polymer nanocomposite resists and their subsequent electroless metallization. The process consists of three simple steps: 1. Fabrication of micro or nanopatterns by lithography or any other direct printing technologies, 2. In-situ synthesis of metal nanoparticle during a post-bake step and 3. Non-electrochemical metallization of nanocomposite patterns. The key point of this procedure is the use of a weak reducing agent so that the metal reduction selectively takes place on the surface of the metal nanoparticle acting as seeds, but not in the bulk of the growing solution. This fabrication method may be very useful for the fabrication of devices profiting of plasmonics (sensing, photovoltaics, optoelectronics…).

**2) Is the innovation developed within the project…:**

|  |
| --- |
| a) Under development  |
| b) Already developed but not yet being exploited  |
| c) being exploited  |
|  |

**3) Characterise the type of innovation** (only to be answered if 2b or 2c is selected)

X

**4) If other, please specify: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_**

**5) Characterise the macro type of innovation** (only to be answered if "under development" is selected for Q2):

**6. Will the innovation be introduced to the market or deployed within a partner:**

|  |
| --- |
| (a) Introduced new to the market (commercial exploitation)  |
| (b) Deployed within a partner (internal exploitation: Changes in organisation, new internal processes implemented, etc.)  |
| (c) No exploitation planned  |

**7. If no exploitation planned, please explain why no exploitation is planned** (answer only if 6(c) is selected)

**8. Is there a clear owner of the innovation in the consortium or multiple owners?**

X

**9. Indicate who is the "owner" of the innovation:**

UVEG

**10. Indicate the step(s) already done (or are foreseen) in the project in order to bring the innovation to (or closer to) the market** (answer only if 6(a) is selected)

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Done | Planned in project | Not Planned | Desirable |
| 1. Technology transfer |  |  |  |  |
| 2. Engagement by Industrial research team of one of their company's business units in project activities |  |  |  |  |
| 3. Pilot |  |  |  |  |
| 4. Capital investment (VC, Angel, other) |  |  |  |  |
| 5. Investment from public authority (national, regional) |  |  |  |  |
| 6. Business plan |  |  |  |  |
| 7. Prototyping |  |  |  |  |
| 8. Market study |  |  |  |  |
| 9. Demonstration or Testing activities |  |  |  |  |
| 10. Feasibility study |  |  |  |  |
| 11. Launch a start-up or spin-off |  |  |  |  |
| 12. Other |  |  |  |  |

**11. If other, please specify**

**12. Indicate which participant(s) (up to a maximum of 3) is/are the key organisation(s) in the project delivering this innovation. For each of these identify under the next question their needs to fulfil their market potential.**

UVEG

**13. Indicate their needs to fulfil their market potential**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Investor readiness training | Investor introductions | Biz plan development | Expanding to more markets | Legal advice (IPR or other) | Mentoring | Partnership with other company (technology or other) | Incubation | Startup accelerator |
| UVEG |   |   |   |   |   |   |   |   |   |

**14. When do you expect that such innovation could be commercialised?** (answer only if 6(a) is selected)

**15. Have any of the project partners…**

(only to be answered if "Done" or "Planned in Project" is chosen for 10.5 "Investment from public authority")

X

**16. Which partners are in discussion with investors (or are planning such discussions)?**

UVEG

(the above questions are to be answered for **each** innovation developed by the project, up to a maximum of 3 innovations)

**General Questions**

(questions below are to be answered once in the project review, not for each innovation)

 **1. How does the consortium engage end-users?**

|  |
| --- |
| End user organisation in the consortium  |
| An end user organisation outside of the consortium is consulted  |
| No end user organisation in the consortium or consulted  |

**2. Are there in the consortium internal IPR issues that could compromise the ability of a project partner to exploit new products/solutions/services, internally or in the market place ?**

|  |
| --- |
| yes  |
| No  |

**4. Which are the external bottlenecks that compromise the ability of project partners to exploit new products, solutions or services, internally or in the market place?**

|  |  |
| --- | --- |
| IPR  | Standards  |
| Regulation  | Financing  |
| Workforce's skills  | Trade issues (between MS, globally)  |
| Others (technology readiness, process maturity) |   |

**5. Indicate how many patents have been applied for by the project: 1**